DE68912459D1 - Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten. - Google Patents

Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten.

Info

Publication number
DE68912459D1
DE68912459D1 DE89116002T DE68912459T DE68912459D1 DE 68912459 D1 DE68912459 D1 DE 68912459D1 DE 89116002 T DE89116002 T DE 89116002T DE 68912459 T DE68912459 T DE 68912459T DE 68912459 D1 DE68912459 D1 DE 68912459D1
Authority
DE
Germany
Prior art keywords
thromboxane
treatment
manufacture
pharmaceutical composition
receptor antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE89116002T
Other languages
English (en)
Other versions
DE68912459T2 (de
Inventor
Lawrence T Friedhoff
Laura L Bolton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Application granted granted Critical
Publication of DE68912459D1 publication Critical patent/DE68912459D1/de
Publication of DE68912459T2 publication Critical patent/DE68912459T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
DE68912459T 1988-09-01 1989-08-30 Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten. Expired - Lifetime DE68912459T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/239,376 US4925873A (en) 1988-09-01 1988-09-01 Method of treating skin injuries using thromboxane A2 receptor antagonists

Publications (2)

Publication Number Publication Date
DE68912459D1 true DE68912459D1 (de) 1994-03-03
DE68912459T2 DE68912459T2 (de) 1994-08-04

Family

ID=22901897

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68912459T Expired - Lifetime DE68912459T2 (de) 1988-09-01 1989-08-30 Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten.

Country Status (13)

Country Link
US (1) US4925873A (de)
EP (1) EP0357030B1 (de)
JP (1) JPH02108635A (de)
AT (1) ATE100320T1 (de)
AU (1) AU632503B2 (de)
CA (1) CA1337930C (de)
DE (1) DE68912459T2 (de)
DK (1) DK175207B1 (de)
HU (1) HUT51137A (de)
IE (1) IE63799B1 (de)
NZ (1) NZ230505A (de)
PT (1) PT91597B (de)
ZA (1) ZA896558B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US5324746A (en) * 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US7910624B1 (en) 1995-03-03 2011-03-22 The Trustees Of Boston University Compositions for the treatment of blood disorders
CA2174737C (en) * 1993-10-29 2008-04-22 Douglas V. Faller Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
DE122005000033I2 (de) 1994-10-21 2006-11-23 Nps Pharma Inc Kalzium-Receptor aktive Verbindungen
GB9424708D0 (en) * 1994-12-07 1995-02-01 Bristol Myers Squibb Co Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
PT907631E (pt) 1996-05-01 2003-10-31 Nps Pharma Inc Compostos inorganicos activos como receptores de ioes
US5994399A (en) * 1997-03-27 1999-11-30 Mckee; Rex N. Method of regenerating collagen-containing tissues with misoprostol
WO1999040883A2 (en) * 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
US7241746B2 (en) * 2003-08-06 2007-07-10 Regena Therapeutics, Lc Method and composition for treating periodontal disease
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
CN102802412A (zh) 2009-12-08 2012-11-28 海玛奎斯特医药公司 用于治疗红细胞病症的方法及低剂量方案
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
WO2012105823A1 (en) 2011-02-02 2012-08-09 Biotropics Malaysia Berhad Cosmetic non therapeutic use of extracts from ficus deltoidea
EP3976198A4 (de) 2019-05-31 2023-07-19 Viracta Subsidiary, Inc. Verfahren zur behandlung von viral assoziiertem krebs mit histon-deacetylase-inhibitoren

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2809377A1 (de) * 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
DE3000377A1 (de) * 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4537981A (en) * 1981-11-09 1985-08-27 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane and 7-oxabicycloheptene compounds
US4416896A (en) * 1982-05-17 1983-11-22 E. R. Squibb & Sons, Inc. 7-Oxabicyclopheptane substituted amino prostaglandin analogs useful in the treatment of thrombolytic disease
US4663336A (en) * 1985-07-01 1987-05-05 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted diamide and its congener prostaglandin analogs useful in the treatment of thrombotic disease
US4673685A (en) * 1986-07-23 1987-06-16 E. R. Squibb & Sons, Inc. Hydroximic acids of 7-oxabicycloheptane substituted ethers and thioethers useful in the treatment of thrombotic disease
US4752616A (en) * 1987-06-29 1988-06-21 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, compositions containing same and method of use

Also Published As

Publication number Publication date
EP0357030A2 (de) 1990-03-07
DE68912459T2 (de) 1994-08-04
CA1337930C (en) 1996-01-16
HUT51137A (en) 1990-04-28
AU632503B2 (en) 1993-01-07
ZA896558B (en) 1990-05-30
IE892755L (en) 1990-03-01
PT91597B (pt) 1995-05-04
DK431589D0 (da) 1989-08-31
EP0357030A3 (en) 1990-08-16
NZ230505A (en) 1997-03-24
ATE100320T1 (de) 1994-02-15
JPH02108635A (ja) 1990-04-20
DK431589A (da) 1990-03-02
US4925873A (en) 1990-05-15
EP0357030B1 (de) 1994-01-19
IE63799B1 (en) 1995-06-14
PT91597A (pt) 1990-03-30
DK175207B1 (da) 2004-07-12
AU4089889A (en) 1990-03-08

Similar Documents

Publication Publication Date Title
DE68912459T2 (de) Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten.
DE1300150T1 (de) Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck
ATE142107T1 (de) Verwendung von angiotensin-ii-antagonisten zur herstellung eines arzneimittels zur behandlung von hyperuricemie
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
DE69001484D1 (de) Verwendung von menschlichen bcdf fuer die herstellung einer zusammensetzung fuer die behandlung von thrombocytopenia.
ATE158183T1 (de) Arzneimittel zur behandlung von anxietas
IT9041503A0 (it) Dispositivo per la cura chirurgica dell'ametropia
ATE66149T1 (de) Pharmazeutische dosierungseinheit zur vorbeugung bzw. behandlung von klimakterischen beschwerden.
DE69501359T2 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
DE69412662D1 (de) Angiotensin II-Antagonisten zur Behandlung von viralen Erkrankungen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE79254T1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
DE69111974T2 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
DE69103624D1 (de) Ipriflavone enthaltende pharmazeutische zubereitungen, verfahren zur herstellung und therapeutische verwendung.
ATE183088T1 (de) Arzneimittel zur behandlung von hauterkrankungen
DE3687233T2 (de) Pharmazeutische zusammensetzungen zur behandlung von hautkrankheiten.
DE68905076T2 (de) Pharmazeutische Zusammensetzung für die Behandlung von Hautwunden.
DK277387A (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
ATE80998T1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
ATE225664T1 (de) Verwendung von humanem alpha 1-sauren glycoprotein zur herstellung einer pharmazeutischen präparation
DE68906028T2 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ATE56360T1 (de) Zusammensetzung zur herstellung eines arzneimittels zur therapeutischen behandlung von hauttrauma.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee